BC Week In Review | Feb 18, 2013
Company News

China Nuokang deal

China Nuokang said it has gone private after shareholders approved a proposal to go private from CEO and Chairman Baizhong Xue and Kingbird Investment Inc. for $0.725 per share in cash, or $5.80 per ADS....
BC Week In Review | Jan 21, 2013
Company News

China Nuokang hematology, cardiovascular news

China Nuokang adjourned its Jan. 15 general meeting of shareholders, which it called to authorize and approve the proposal to go private from CEO and Chairman Baizhong Xue. The company decided to adjourn the meeting...
BC Week In Review | Oct 1, 2012
Company News

China Nuokang deal

China Nuokang said its board approved a proposal to go private from CEO and Chairman Baizhong Xue. In May, Xue offered to acquire the 38.8% of China Nuokang that he does not own or control...
BC Extra | Sep 28, 2012
Company News

China Nuokang going private

China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) said its board approved a proposal to go private from CEO and Chairman Baizhong Xue. In May, Xue offered to acquire the 39.8% of China Nuokang that he does not...
BC Week In Review | May 14, 2012
Company News

China Nuokang hematology, cardiovascular news

China Nuokang's board received a preliminary, non-binding proposal from the company's CEO and Chairman Baizhong Xue to acquire the 39.8% of the company that Xue does not own or control for $5.80 per ADS, or...
BioCentury | Jan 25, 2010
Analyst Picks & Changes

Analysts Picks & Changes

Analysts Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 1/22 cls China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) Jefferies Marko Kozul New Buy -11% $7.98 Kozul set a $13 target. He expect the shares to...
BioCentury | Dec 14, 2009
Finance

Ebb & Flow

Investors in oncology company Gloucester Pharmaceuticals Inc. are looking at a 3.5X-6.5X return on an acquisition by Celgene Corp. (NASDAQ: CELG), making it a model for how to execute in-licensing and keep costs under control....
BC Extra | Dec 11, 2009
Financial News

China Nuokang prices IPO

China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) raised $40.7 million through the sale of 4.5 million American Depositary Shares at $9 per ADS in an IPO underwritten by Jefferies and Oppenheimer. The deal came in below the...
BioCentury | Dec 7, 2009
Finance

Ebb & Flow

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...
BC Extra | Nov 24, 2009
Top Story

Ironwood, China Nuokang planning IPOs

Ironwood Pharmaceuticals Inc . (Cambridge, Mass.) and China Nuokang Bio-Pharmaceutical Inc. (Shenyang, China) filed for IPOs on Friday. Ironwood filed to raise up to $172.5 million in an IPO underwritten by JPMorgan; Morgan Stanley; Credit Suisse;...
Items per page:
1 - 10 of 11